IL13 and asthma: The magnitude of the variation was small, suggesting that the time that periostin levels are measured is unlikely to influence treatment decisions if predicting responsiveness to, or eligibility for monoclonal antibody therapy directed against IL-4Ra, IL-13, IgE or other components of type-2 inflammation in asthma.